Đang chuẩn bị liên kết để tải về tài liệu:
Determining genomic profile and application in treatment of non amplified MYCN neuroblastoma patient

Neuroblastoma is the most common extracranial solid cancer of childhood and is characterized by a remarkable biological heterogeneity, cause multiple genetic changes. The genetic profiles are the powerful tools for the clinician in risk stratification and treatment tailoring in neuroblastoma patients. | Journal of military pharmaco-medicine no1-2019 DETERMINING GENOMIC PROFILE AND APPLICATION IN TREATMENT OF NON-AMPLIFIED MYCN NEUROBLASTOMA PATIENT Vu Dinh Quang1; Nguyen Thi Hong Van2; Phung Tuyet Lan1 Nguyen Xuan Huy1; Ngo Diem Ngoc1; Bui Ngoc Lan1; Pham Duy Hien1 Le Dinh Cong1; Le Thi Kim Ngoc1; Hoang Ngoc Thach1 Hoang Quoc Chinh3; Nguyen Thanh Liem3; Le Thanh Hai1 SUMMARY Background: Neuroblastoma is the most common extracranial solid cancer of childhood and is characterized by a remarkable biological heterogeneity, cause multiple genetic changes. The genetic profiles are the powerful tools for the clinician in risk stratification and treatment tailoring in neuroblastoma patients. This will increase the chance of treatment’s success and minimize the dose of chemotherapy for these patients. Subjects: 6 neuroblastoma patients under 18 months, non-amplified MYCN were diagnosed and treated in National Children’s Hospital. Method: The CGH technique is performed on the Agilent’s system with the 400k chip at Vinmec International Hospital. Results: 4 patients were found the numerical chromosomal abnormalities (both stage L2), the others were the segmental chromosomal abnormalities (1 stage L2 and 1 stage M). Based on this results, 4/5 patients could be stopped the chemotherapy, 1 patient had to continue the treatment. The stage M patient had the 50% of chance of success in highdose chemotherapy and stem cell transplantation. Conclusion: The genomic profile by CGH is established successfully in Vietnam. The integration of this technique allows more precise prognostication and refined treatment assignment which contribute to improve survival with decreased toxicity. * Keywords: Neuroblastoma; Genomic hybridization. INTRODUCTION Neuroblastoma (NBL), an embryonic tumour of the sympathetic nervous system, often affects children age 5 or younger [1]. It’s the most common solid tumor in first year of life, with the prevalence approximately 1/7,000 live births. The median .